Imperial College London

Professor Paul M. Matthews

Faculty of MedicineDepartment of Medicine

Edmond and Lily Safra Chair and Head of Brain Sciences



+44 (0)20 7594 2855p.matthews




Ms Siobhan Dillon +44 (0)20 7594 2855




E502Burlington DanesHammersmith Campus






BibTex format

author = {Enzinger, C and Fazekas, F and Matthews, PM and Ropele, S and Schmidt, H and Smith, S and Schmidt, R},
journal = {Research and Practice in Alzheimer's Disease},
pages = {227--233},
title = {Factors associated with progression of brain atrophy during ageing: 6 year follow-up from the Austrian stroke prevention study},
volume = {11},
year = {2006}

RIS format (EndNote, RefMan)

AB - Neuroimaging techniques are increasingly used to study mechanisms leading to cognitive impairment. In particular, brain atrophy has been proposed as a surrogate marker of dementia. However, little is known regarding confounding factors which might modulate the evolution of brain atrophy during ageing. We therefore determined the rate of atrophy over 6 years for 201 participants (F/M=96/105; 59.8±5.9 yrs) in the Austrian Stroke Prevention Study and probed the impact of baseline variables on its progression. The mean annual brain volume change was -0.40±0.29%. The rate of brain atrophy was significantly higher in subjects of greater age and those with higher HbA1c, higher body-mass-index, high alcohol intake, severe white matter hyperintensities, and in APOEε4-carriers. Multivariate analysis suggested that baseline brain volume, HbA1cand the extent of white matter hyperintensities explain a major proportion of variance in the rates of brain atrophy. These results indicate that neurologically asymptomatic elderly experience continuing brain volume loss, which appears to accelerate with age. HbA1cwas identified as a risk factor for a greater rate of brain atrophy. Clustering of factors associated with the so-called "metabolic syndrome" in subjects with high HbA1csuggests a link between this syndrome and late-life brain tissue loss. Together, this underscores the need to control for confounding factors in future Clinical trials and indicates possible new directions for intervention.
AU - Enzinger,C
AU - Fazekas,F
AU - Matthews,PM
AU - Ropele,S
AU - Schmidt,H
AU - Smith,S
AU - Schmidt,R
EP - 233
PY - 2006///
SN - 1284-8360
SP - 227
TI - Factors associated with progression of brain atrophy during ageing: 6 year follow-up from the Austrian stroke prevention study
T2 - Research and Practice in Alzheimer's Disease
VL - 11
ER -